217 related articles for article (PubMed ID: 29758012)
21. Constitutive control of AKT1 gene expression by JUNB/CJUN in ALK+ anaplastic large-cell lymphoma: a novel crosstalk mechanism.
Atsaves V; Zhang R; Ruder D; Pan Y; Leventaki V; Rassidakis GZ; Claret FX
Leukemia; 2015 Nov; 29(11):2162-72. PubMed ID: 25987255
[TBL] [Abstract][Full Text] [Related]
22. Gene expression profiling of isolated tumour cells from anaplastic large cell lymphomas: insights into its cellular origin, pathogenesis and relation to Hodgkin lymphoma.
Eckerle S; Brune V; Döring C; Tiacci E; Bohle V; Sundström C; Kodet R; Paulli M; Falini B; Klapper W; Chaubert AB; Willenbrock K; Metzler D; Bräuninger A; Küppers R; Hansmann ML
Leukemia; 2009 Nov; 23(11):2129-38. PubMed ID: 19657361
[TBL] [Abstract][Full Text] [Related]
23. ALK-dependent control of hypoxia-inducible factors mediates tumor growth and metastasis.
Martinengo C; Poggio T; Menotti M; Scalzo MS; Mastini C; Ambrogio C; Pellegrino E; Riera L; Piva R; Ribatti D; Pastorino F; Perri P; Ponzoni M; Wang Q; Voena C; Chiarle R
Cancer Res; 2014 Nov; 74(21):6094-106. PubMed ID: 25193384
[TBL] [Abstract][Full Text] [Related]
24. Brefeldin A exerts differential effects on anaplastic lymphoma kinase positive anaplastic large cell lymphoma and classical Hodgkin lymphoma cell lines.
Toda T; Watanabe M; Kawato J; Kadin ME; Higashihara M; Kunisada T; Umezawa K; Horie R
Br J Haematol; 2015 Sep; 170(6):837-46. PubMed ID: 26105086
[TBL] [Abstract][Full Text] [Related]
25. CD147 a direct target of miR-146a supports energy metabolism and promotes tumor growth in ALK+ ALCL.
Montes-Mojarro IA; Steinhilber J; Griessinger CM; Rau A; Gersmann AK; Kohlhofer U; Fallier-Becker P; Liang HC; Hofmann U; Haag M; Klapper W; Schaeffeler E; Pichler BJ; Schwab M; Fend F; Bonzheim I; Quintanilla-Martinez L
Leukemia; 2022 Aug; 36(8):2050-2063. PubMed ID: 35676454
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA 96 is a post-transcriptional suppressor of anaplastic lymphoma kinase expression.
Vishwamitra D; Li Y; Wilson D; Manshouri R; Curry CV; Shi B; Tang XM; Sheehan AM; Wistuba II; Shi P; Amin HM
Am J Pathol; 2012 May; 180(5):1772-80. PubMed ID: 22414602
[TBL] [Abstract][Full Text] [Related]
27. The oncogenic JUNB/CD30 axis contributes to cell cycle deregulation in ALK+ anaplastic large cell lymphoma.
Atsaves V; Lekakis L; Drakos E; Leventaki V; Ghaderi M; Baltatzis GE; Chioureas D; Jones D; Feretzaki M; Liakou C; Panayiotidis P; Gorgoulis V; Patsouris E; Medeiros LJ; Claret FX; Rassidakis GZ
Br J Haematol; 2014 Nov; 167(4):514-23. PubMed ID: 25145835
[TBL] [Abstract][Full Text] [Related]
28. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
29. A positive feedback loop involving the Wnt/β-catenin/MYC/Sox2 axis defines a highly tumorigenic cell subpopulation in ALK-positive anaplastic large cell lymphoma.
Wu C; Zhang HF; Gupta N; Alshareef A; Wang Q; Huang YH; Lewis JT; Douglas DN; Kneteman NM; Lai R
J Hematol Oncol; 2016 Nov; 9(1):120. PubMed ID: 27821172
[TBL] [Abstract][Full Text] [Related]
30. IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma.
Dien Bard J; Gelebart P; Anand M; Zak Z; Hegazy SA; Amin HM; Lai R
Am J Pathol; 2009 Aug; 175(2):825-34. PubMed ID: 19608866
[TBL] [Abstract][Full Text] [Related]
31. Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126.
Ito M; Zhao N; Zeng Z; Chang CC; Zu Y
Cancer Gene Ther; 2010 Sep; 17(9):633-44. PubMed ID: 20448669
[TBL] [Abstract][Full Text] [Related]
32. miR-135b mediates NPM-ALK-driven oncogenicity and renders IL-17-producing immunophenotype to anaplastic large cell lymphoma.
Matsuyama H; Suzuki HI; Nishimori H; Noguchi M; Yao T; Komatsu N; Mano H; Sugimoto K; Miyazono K
Blood; 2011 Dec; 118(26):6881-92. PubMed ID: 22042699
[TBL] [Abstract][Full Text] [Related]
33. Genetics of anaplastic large cell lymphoma.
Zeng Y; Feldman AL
Leuk Lymphoma; 2016; 57(1):21-7. PubMed ID: 26104084
[TBL] [Abstract][Full Text] [Related]
34. Expression of granzyme B sensitizes ALK+ ALCL tumour cells to apoptosis-inducing drugs.
Pearson JD; Zhang J; Wu Z; Thew KD; Rowe KJ; Bacani JT; Ingham RJ
Mol Cancer; 2014 Aug; 13():199. PubMed ID: 25168906
[TBL] [Abstract][Full Text] [Related]
35. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
[TBL] [Abstract][Full Text] [Related]
36. Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes.
Lamant L; de Reyniès A; Duplantier MM; Rickman DS; Sabourdy F; Giuriato S; Brugières L; Gaulard P; Espinos E; Delsol G
Blood; 2007 Mar; 109(5):2156-64. PubMed ID: 17077326
[TBL] [Abstract][Full Text] [Related]
37. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma.
Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S
Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968
[TBL] [Abstract][Full Text] [Related]
38. Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts.
Scarfò I; Pellegrino E; Mereu E; Kwee I; Agnelli L; Bergaggio E; Garaffo G; Vitale N; Caputo M; Machiorlatti R; Circosta P; Abate F; Barreca A; Novero D; Mathew S; Rinaldi A; Tiacci E; Serra S; Deaglio S; Neri A; Falini B; Rabadan R; Bertoni F; Inghirami G; Piva R;
Blood; 2016 Jan; 127(2):221-32. PubMed ID: 26463425
[TBL] [Abstract][Full Text] [Related]
39. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
[TBL] [Abstract][Full Text] [Related]
40. A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.
Abate F; Todaro M; van der Krogt JA; Boi M; Landra I; Machiorlatti R; Tabbò F; Messana K; Abele C; Barreca A; Novero D; Gaudiano M; Aliberti S; Di Giacomo F; Tousseyn T; Lasorsa E; Crescenzo R; Bessone L; Ficarra E; Acquaviva A; Rinaldi A; Ponzoni M; Longo DL; Aime S; Cheng M; Ruggeri B; Piccaluga PP; Pileri S; Tiacci E; Falini B; Pera-Gresely B; Cerchietti L; Iqbal J; Chan WC; Shultz LD; Kwee I; Piva R; Wlodarska I; Rabadan R; Bertoni F; Inghirami G;
Leukemia; 2015 Jun; 29(6):1390-401. PubMed ID: 25533804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]